Gilead Sciences (GILD), Merck (MRK) Join Forces on Long-Acting HIV Therapy - WSJ

Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) are joining forces to develop a long-acting HIV therapy, according to the Wall Street Journal.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Biogen (BIIB) Receives Positive CHMP Opinion for TOFIDENCE
• Business First Bancshares Inc. (BFST) to acquire Oakwood Bancshares